Odyssey Health, Inc. is a publicly held company focused on acquiring and developing medical products, specifically the CardioMap heart monitoring and screening device and the Save A Life choking rescue device. The company’s business model involves developing or acquiring medical related technologies, engaging third parties for development and manufacturing, and distributing the products through third party channels or its own direct efforts. All product candidates remain in research and development and have not yet received regulatory clearance for commercial sale.

Odyssey Health, Inc. anticipates generating revenue primarily through licensing and distribution agreements for its product candidates once they obtain regulatory clearance. Under this model, the company plans to charge an initial license fee and ongoing royalties based on gross sales to partners or distributors in the United States and internationally. Until its products receive approval, the company does not generate operating revenue.

The company operates through the following segments.

• Single reportable segment: This segment encompasses all of the company's business activities, including the development and commercialization of the CardioMap and Save A Life medical devices.

Odyssey Health, Inc. occupies an early stage position in the medical device industry, focusing on novel diagnostics and emergency rescue tools that aim to improve upon existing electrocardiograph and anti choking solutions. Its CardioMap technology competes with devices such as the CardioResting (Nasiff) system, Welch Allyn PC based electrocardiograph, and QardioCore wireless ambulatory ECG monitor, but claims superior sensitivity and 3D visualization capabilities not offered by those products. The Save A Life choking rescue device faces competition from the Dechoker, LifeVac, and Act+Fast Heimlich trainer, yet asserts a distinct vacuum based mechanism that can dislodge obstructions quickly and safely. Overall, the company’s competitive advantage lies in its proprietary technologies that address unmet needs for early cardiac detection and rapid choking intervention, although it currently lacks regulatory clearance and commercial sales.

Odyssey Health, Inc. intends to sell its products to a broad range of users including cardiologists, physicians, clinics, hospitals, fitness centers, sports teams, emergency medical services, and the general public for its CardioMap device, while the Save A Life choking rescue device is aimed at consumers, healthcare providers, and first responder organizations. No specific customer names are disclosed in the filing.